Newsletter Subject

FDA Approves First Oral Antiviral Drug for COVID-19

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Thu, May 25, 2023 10:51 PM

Email Preheader Text

Daily Headlines Thursday, May 25, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT T

[MEDPAGE TODAY]( Daily Headlines Thursday, May 25, 2023 Today's Top Stories for {NAME} [INFECTIOUS DISEASE]( [FDA Approves First Oral Antiviral Drug for COVID-19]( [MEETING COVERAGE]( [No Access to Routine Healthcare Biggest Barrier to HPV Vaccination]( [SURGERY]( [OTC Hearing Aids Are Here, But Are They Shaking Things Up?]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Novel Approaches for the Treatment of Acute Myeloid Leukemia]( [MEETING COVERAGE]( [Medicaid Expansion Tied to Better Outcomes in Black Patients With GI Cancers]( [MEETING COVERAGE]( [Less-Invasive Surgery for Pancreatic Cancer Proves Safe, Effective]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [MEETING COVERAGE]( [Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS]( CME SPOTLIGHT [New and Emerging Immunotherapeutic Approaches to Advanced Melanoma]( [MEETING COVERAGE]( [Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients]( [MEETING COVERAGE]( [Trial Results Spark Talk of Curing More Metastatic Cervical Cancers]( [NEUROLOGY]( [Brain Bleed Outcomes Improve With Bundled Care Strategy]( CME SPOTLIGHT [Navigating the Latest Evidence on Multi-Cancer Early Detection Technologies]( [MEETING COVERAGE]( [Psilocybin Works Just as Well for Depression With or Without Antidepressant]( [POP MEDICINE]( ['Love Is Blind' in Healthcare; Donut Surgery; Reaction to Hank Green's Lymphoma]( [MEETING COVERAGE]( [Gas Stove Use Linked to Indoor Pollutant Levels]( CME SPOTLIGHT [State-of-the-Art Care for Myelodysplastic Syndromes and Myeloproliferative Neoplasms]( [NEUROLOGY]( [Long COVID Now Has a Framework to Define It]( [RADIOLOGY]( [Lung Cancer Screening Results Influence Follow-Up Adherence]( [MEETING COVERAGE]( [Immunotherapy Combo Shows Promise in Tough-to-Treat, Early Bladder Cancer]( CME SPOTLIGHT [Advancing Care of Patients With Sickle Cell Disease]( [SPECIAL REPORTS]( [Burn Victim Pics Shared? Foreign Botox Settlement; Defibrillator Fire Death Lawsuit]( [GASTROENTEROLOGY]( [A Close Look at the Data Backing Upadacitinib's Approval in Crohn's]( [GASTROENTEROLOGY]( [Prior Auth for Colonoscopy Will Put Patients at Risk, Says ACG's Dayna Early]( CME SPOTLIGHT [Advancing AML Care: A Targeted Approach]( [OPINION]( [What Our Patients With Dense Breasts Deserve to Know]( [ASCO READING ROOM]( [Wassim Kassouf, MD, on Whole Pelvis Radiation in Muscle-Invasive Bladder Cancer]( [MEETING COVERAGE]( [Ketamine Matches 'Gold Standard' in Major Depression Trial]( # Weekly Survey [Prescribe Weight Loss Drugs Based on BMI Alone?]( GLP-1 agonists have been approved for obesity based on their BMI, but [some argue]( BMI isn't a good measure of health[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-05-25&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

26/03/2024

Sent On

26/03/2024

Sent On

26/03/2024

Sent On

25/03/2024

Sent On

25/03/2024

Sent On

25/03/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.